PF-03394197 Oclacitinib maleate NEW

‌Oclacitinib Maleate (CAS 1640292-55-2)‌
🌟 ‌ChemicalBook Product Profile‌

📌 ‌Product Overview‌

‌Oclacitinib Maleate‌ (C₁₉H₂₇N₅O₆S) is a ‌selective JAK1 inhibitor‌ with a molecular weight of ‌453.51 g/mol‌. This ‌white crystalline powder‌ (≥99% purity, HPLC-validated) is specifically formulated for ‌veterinary use‌, effectively treating allergic dermatitis and pruritus in dogs by targeting JAK1-dependent cytokines. It minimizes off-target effects on JAK2/JAK3, ensuring safety and efficacy. Available in ‌1kg/5kg/25kg‌ sealed packaging, stable for ‌2 years‌ under dry, light-protected storage (-20°C recommended).

‌Google Keywords‌: Oclacitinib Maleate CAS 1640292-55-2, JAK1 Inhibitor API Supplier, Veterinary Dermatology Drug Intermediate, GMP-Certified Animal Health Raw Material

✅ ‌Key Advantages‌

       🔹 ‌High Selectivity‌

• IC50 of ‌10 nM for JAK1‌ | 74-fold selectivity over JAK2/JAK3.
  🔹 ‌Pharmaceutical-Grade Purity‌

• ≥99% purity (HPLC/NMR validated) | Complies with ‌EP/USP‌ standards.
  🔹 ‌Stability Assurance‌

• Maintains potency for ‌2 years‌ under recommended storage conditions.

🏥 ‌Application Fields‌

1. ‌Veterinary Medicine‌: Core API for oral tablets targeting canine allergic dermatitis and pruritus.

2. ‌Pharmaceutical R&D‌: Key intermediate in JAK inhibitor development and preclinical studies.

3. ‌Global API Supply‌: Bulk production for veterinary drug manufacturers.

📜 ‌Quality Certifications‌

• ‌Testing Methods‌: HPLC, NMR, mass spectrometry, microbial limit testing.

• ‌Certifications‌: ‌GMP‌, ‌ISO 9001‌, and ‌ICH stability guidelines‌ compliance.

📊 ‌Market Trends‌

The ‌global veterinary dermatology market‌ is projected to grow at ‌7.5% CAGR (2025-2030)‌, driven by rising pet ownership and demand for targeted therapies. JAK inhibitors like Oclacitinib dominate ‌30% of the veterinary anti-inflammatory drug segment‌, with Asia-Pacific as the leading API production hub.

📩 ‌Contact us for COA, bulk pricing, and custom synthesis!